Johnson & Johnson (JNJ)

Investment Thesis

👁 What to Watch

• Q3 2026 earnings release and any further guidance adjustments for FY2026.
• Progress on Stelara biosimilar launch timelines and market share erosion rates.
• Integration milestones for Firefly Bio and Halda Therapeutics acquisitions.
• Updates on talc litigation settlements or legal rulings in pending cases.
• Dividend payment dates, including the next ex-date in late August 2026.
• Changes in net debt levels following completion of acquisition-related payments.
• Analyst consensus target price revisions as the stock approaches $273.

Johnson & Johnson exhibits a robust financial profile, underscored by a Z-Score of 4.58 which places it firmly in the safe zone with very low bankruptcy risk. The F-Score of 7/9 indicates a strong improver, driven by solid profitability and efficiency metrics, though leverage scores are moderate. This combination suggests a company that is financially resilient while actively managing its balance sheet.

Leverage remains conservative with Net Debt/EBITDA at 0.7x, despite recent acquisition activity increasing absolute debt levels. Interest coverage is strong at 25.7x, providing ample cushion for servicing obligations. The current ratio of 1.09 is somewhat weak, indicating a tighter short-term liquidity position, but this is offset by the quick ratio of 0.81 and strong operating cash flow generation.

Cash flow quality is adequate with OCF/Net Income at 0.92x, showing that reported earnings are well-backed by actual cash generation. The high proportion of goodwill and intangibles (49.3% of assets) reflects the company's acquisition strategy, but this trend has been declining over the past decade, suggesting a maturation of the balance sheet.

Profitability metrics are exceptional, with a gross margin of 72.8% and operating margin of 27.2%, reflecting the high-value nature of its pharmaceutical portfolio. Net margin stands at 28.5%, demonstrating efficient cost management across the organization. These margins support strong returns on capital, with ROE at 32.9% and ROCE at 23.1%, indicating effective deployment of shareholder funds.

Free cash flow margin is strong at 20.9%, providing significant internal funding for dividends, buybacks, and acquisitions. The consistency of these margins over time, despite integration challenges from recent deals, underscores the quality of the underlying business model. ROA of 13.5% further confirms that the company generates substantial value relative to its total asset base.

Revenue growth is steady at 6.0% over the past year, with a 3-year CAGR of 5.6%. While long-term revenue growth has moderated to 2.7% over five years, recent quarters have shown acceleration, with Q2 2026 revenue up 6.6% YoY. The company is on track for its first-ever $100B+ revenue year, driven by strong performance in Innovative Medicine.

Earnings growth has been more volatile, with a 1-year increase of 90.6% largely due to the normalization from prior year legal charges. However, the 5-year EPS CAGR of 6.1% indicates consistent underlying improvement. Forward guidance suggests continued momentum, with revenue expected to grow 7.4% in the current fiscal year and 7.6% next year, supported by pipeline expansion and operational efficiencies.

Valuation is the primary drag on the investment case, with a Value sub-score of just 2.9. The trailing P/E stands at 31.5x, which is expensive relative to historical norms and peers. The forward P/E of 22.9x implies significant earnings growth expectations (37.1% implied EPS growth), leaving little room for disappointment if execution falters.

Other multiples also reflect a premium: EV/EBITDA at 20.1x, Price/FCF at 35.2x, and PEG ratio at 4.75. The dividend yield is modest at 1.95%, offering limited income support compared to higher-yielding healthcare peers. Analyst consensus targets are around $273, suggesting limited upside from current levels if the stock maintains its recent rally.

The high valuation metrics suggest that the market is pricing in sustained outperformance and successful integration of recent acquisitions. Any slippage in Stelara sales or pipeline delays could trigger a significant re-rating, given the lack of valuation cushion.

Johnson & Johnson is a Dividend King, having increased its payout for 64 consecutive years. The dividend was raised to $1.34 per quarter in April 2026, an annualized $5.36, representing a 3.1% increase. This commitment to shareholder returns is supported by strong free cash flow generation and a moderate payout ratio of 51%.

The 5-year dividend CAGR is 5.0%, providing reliable income growth for investors. While the current yield of 1.95% is low due to the high share price, the consistency and coverage of the dividend make it an attractive feature for income-focused portfolios. The company's strong cash flow position ensures that the dividend remains well-covered even during periods of acquisition activity.